초록 ▼

A demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is moldable, biocompatible, slowly reso

A demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is moldable, biocompatible, slowly resorbable, and soluble in tissue fluids, and non-extrudable. The composition delivers a biologically active product to animals and humans that will enhance bone formation at sites where bone is lost, deficient, or present in suboptimal amounts. The composition can further comprise calcium, an antioxidant such as Vitamin E or Vitamin C, or a hydrophilic polymer such as methylcellulose or hydroxypropyl methylcellulose.

대표청구항 ▼

A demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is moldable, biocompatible, slowly reso

A demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is moldable, biocompatible, slowly resorbable, and soluble in tissue fluids, and non-extrudable. The composition delivers a biologically active product to animals and humans that will enhance bone formation at sites where bone is lost, deficient, or present in suboptimal amounts. The composition can further comprise calcium, an antioxidant such as Vitamin E or Vitamin C, or a hydrophilic polymer such as methylcellulose or hydroxypropyl methylcellulose. starch. 13. A method according to claim 1, wherein the polymer comprises poly(lactide-co-caprolactone) copolymer, polyhydroxybutyrate-polyhydroxyvalerate copolymer, polybutadiene, polymethyl methacrylate, polyhydroxyethyl methacrylate, polyvinyl acetate, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, cellulose acetate, or cellulose acetate butyrate. 14. The method of claim 1, wherein the polymer comprises a poly(lactide-co-glycolide) copolymer, a polylactide homopolymer, or a polyglycolide homopolymer. 15. The method of claim 1, wherein the micropshere comprises two or more groups of microspheres, wherein each group contains a different neuroactive molecule. 16. The method of claim 1, wherein the neuroactive molecule is dopamine and the polymer is a poly(lactide-co-glycolide) copolymer. 17. The method of claim 1, wherein the neuroactive molecule is dopamine and the polymer is a polycaprolactone. 18. The method of claim 1, wherein the neuroactive molecule is dopamine and the polymer is a polyhydroxybutyrate-polyhydroxyvalerate copolymer. 19. The method of claim 1, wherein the neuroactive molecule is noradrenaline and the polymer is a poly(lactide-co-glycolide) copolymer. 20. The method of claim 1, wherein the neuroactive molecule is norepinephrine and the polymer is a poly(lactide-co-glycolide) copolymer. 21. The method of claim 1, wherein the neuroactive molecule is from 1% to 80% by weight of the microsphere. 22. The method of claim 1, wherein the treatment is for a patient with a neurologic disease and the neurologic disease is Parkinson's disease, amyotrophic lateral sclerosis, Huntington's chorea, Alzheimer's disease, epilepsy, or tardive dyskinesia. 23. The method of claim 1, wherein the treatment is for a patient with a neurologic injury and the neurologic injury is a spinal cord injury. 24. The method of claim 1, wherein the central nervous system is brain tissue. 25. The method of claim 1, wherein the central nervous system is spinal cord tissue.